AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03976323 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03976323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT03976323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT03976323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT03976323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT03976323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT03976323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT03976323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets
Study NCT01475292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568
Description: RV568 100 ug administered via a nebuliser once daily for 14 days
Study NCT01475292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via a nebuliser once daily for 14 days
Study NCT04211324 — intervention group
Intervention type: DEVICE
Intervention: TENS
Description: Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
Study NCT04211324 — intervention group
Intervention type: DEVICE
Intervention: electro-acupuncture
Description: Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
Study NCT02827552 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: skin biopsy
Description: skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
Study NCT03690258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable load exercise
Description: This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
Study NCT01915875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sophrology sessions at home
Description: The sophrology is a dynamic method of physical and psychical relaxation
Study NCT02749721 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vortioxetine
Description: Open-label vortioxetine
Study NCT00312377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: infusion
Study NCT00312377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: infusion
Study NCT00312377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: oral
Study NCT01085929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Description: Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
Study NCT04319198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hiy
Description: Administered intravenously
Study NCT03654742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tonsillectomy
Description: removal of tonsil tissue as described in the study arms
Study NCT02160483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging
Description: 3 Tesla magnetic resonance imaging
Study NCT01285960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Treatment UF V2
Description: Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
Study NCT00473746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
Study NCT00473746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
Study NCT00473746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone/prednisolone or dexamethasone
Description: prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
Study NCT00667420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab, epirubicin, oxaliplatin, xeloda
Description: pilot study
Study NCT04695041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days
Study NCT04695041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
Study NCT04695041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
Study NCT04695041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
Study NCT03331458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exrecise intervention
Description: Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
Study NCT02255149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone/Mesh
Description: A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
Study NCT03167606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile
Description: Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
Study NCT04067739 — intervention group
Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study
Study NCT04423380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH3051 capsule treatment
Description: Starting dose 20mg,oral administered twice daily.If tolerated subsequent cohorts will test increasing doses (40mg,60mg,80mg,100mg) of SH3051.
Study NCT01326663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication Trial
Study NCT01326663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medication Trial
Study NCT06451653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men in Maternity Health (MiM) Intervention
Description: The six-month MiM education program focused on maternal health education for male partners of pregnant women in the intervention area. Assigned midwives offered two-hour-long, face-to-face health education and discussion sessions at five selected health centres every second and fourth Sunday, respectively, to accommodate participants' work schedules. Attendance consistently remained high at 80% of participants every month, with home visits for absentees to provide health education.
Study NCT03069976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Flagyl x 14 days.
Study NCT01693809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT04146805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409
Description: For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
Study NCT04146805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo
Description: Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
Study NCT00354419 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo radiotherapy
Study NCT00354419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00354419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT02959164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level
Study NCT00354419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV
Study NCT00354419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Undergo transplantation
Study NCT00354419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or orally
Study NCT00354419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative study
Study NCT00354419 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative study
Study NCT00354419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC
Study NCT04268797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR rTMS
Description: high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days
Study NCT04268797 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: SHAM HF rTMS coil once daily x 20 days
Study NCT02959164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level
Study NCT02516735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-scan with magnification
Study NCT02516735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopy
Study NCT03178695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous PRP injection into human ovarian tissue
Description: Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
Study NCT02786524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Symptom Management and Supportive Care
Description: Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
Study NCT01525173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% brimonidine tartrate ophthalmic solution
Description: 1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
Study NCT01525173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.01% bimatoprost ophthalmic solution
Description: 1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
Study NCT01525173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% hypromellose lubricant eye drops
Description: 1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
Study NCT01525173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% ophthalmic solution
Description: 1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
Study NCT03706222 — intervention group
Intervention type: DRUG
Intervention: elbasvir/grazoprevir
Description: Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
Study NCT02117427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: Erythropoietin secreted by TARGTEPO transduced with MDGN201
Study NCT01662960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: A home-based therapy involving mirrored visual feedback
Study NCT01662960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Divider therapy
Description: A home-based therapy involving removed visual feedback.
Study NCT01503658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel+Aspirin
Description: Clopidogrel 75 mg, Aspirin 100 mg
Study NCT00898508 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT00898508 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT00898508 — intervention group
Intervention type: GENETIC
Intervention: proteomic profiling
Study NCT00898508 — intervention group
Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00898508 — intervention group
Intervention type: OTHER
Intervention: fluorescent antibody technique
Study NCT00898508 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry staining method
Study NCT00898508 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT00898508 — intervention group
Intervention type: OTHER
Intervention: liquid chromatography
Study NCT00898508 — intervention group
Intervention type: OTHER
Intervention: mass spectrometry
Study NCT00898508 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Study NCT00898508 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Study NCT02382224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Worry Exposure for GAD
Description: WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
Study NCT02382224 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 12-week Waitlist
Description: Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
Study NCT04643691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg and Spironolactone 25 mg pillules oral use
Description: Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
Study NCT02316054 — intervention group
Intervention type: DEVICE
Intervention: MPHI
Description: addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
Study NCT00989053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: 10 mg/d for a duration of 8 weeks
Study NCT00989053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 1 pill per day for 8 weeks
Study NCT00989053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill per day for 8 weeks
Study NCT00508651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-560
Description: MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson\^TM luer slip tip syringes. Each 0.2 mL dose contained 10\^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
Study NCT00508651 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was a frozen preparation filled into Becton Dickinson\^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
Study NCT01104181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HC2 collection kit with a swab or brush
Description: We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
Study NCT02203539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to normal light
Description: exposure for 60 minutes in duration
Study NCT02203539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to bright light
Description: exposure to bright light for 60 minutes of duration
Study NCT02203539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to blue-enriched light
Description: exposure to blue-enriched light for 60 minutes of duration
Study NCT04579393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
Study NCT03204851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Healing
Description: Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
Study NCT02016235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphorus Supplement
Description: 250 mg po qid
Study NCT02016235 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: Baseline blood and urine measurements only
Study NCT03882801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.
Study NCT03882801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
Study NCT01085929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Aspiration
Description: Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
Study NCT02766673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate
Description: Subjects will receive a dose of study medication every 4 hours for 24 total hours
Study NCT02766673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Subjects will receive a dose of study medication every 4 hours for 24 total hours
Study NCT02360774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
Study NCT02360774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
Study NCT00921297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Cataract Surgery
Description: Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
Study NCT03268590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Persons will undergo MRI, EEG, and complete computerized cognitive testing in baseline room air. Persons will then breathe 100% pure oxygen and undergo MRI, EEG, and complete computerized cognitive testing. Persons will serve as their own controls.
Study NCT00531011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V® Everolimus Eluting Coronary Stent System
Description: Coronary artery placement of a drug-eluting stent
Study NCT00531011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
Description: Coronary artery placement of a drug-eluting stent
Study NCT02139982 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: specific nerve block
Description: specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
Study NCT02139982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Different concentration of ropivacaine